Life sciences news

Acuitas Therapeutics filed a complaint against CureVac SE seeking inventorship: Pfizer & BioNtech potentially in the crosshairs

Posted on by

SOPHIA ANTIPOLIS, France – November 27, 2023 │Acuitas Therapeutics filed a complaint on November 13, 2023, against CureVac SE seeking a declaratory judgment of inventorship regarding the US patents 11,241,493; 11,471,525; 11,576,966; and 11,596,686 (collectively referred to as Patent Family ‘493). According to the complaint (Case 3:23-cv-00764), the patents in question were wrongfully assigned to[…]

ReNAgade Therapeutics unveiled new LNPs for delivering mRNA to extra-hepatic tissues: Patent analysis on its proprietary ionizable lipids

Posted on by

SOPHIA ANTIPOLIS, France – November 06, 2023 │ReNAgadeTherapeutics, a company founded in 2021 and based in Cambridge, presented preclinical data demonstrating a new and proprietary method of delivering mRNA to extra-hepatic tissues in non-human primate using lipid nanoparticles (LNPs) at the 11th International mRNA Health Conference, taking place from October 31 to November 2, 2023[…]

Cellectis is a strategic intellectual property partner for AstraZeneca in the field of off-the-shelf immunotherapies

Posted on by

SOPHIA ANTIPOLIS, France – November 02, 2023 │Cellectis and AstraZeneca announced their partnership through a Joint Research Collaboration Agreement, an $80 million initial equity investment, and a memorandum of understanding for an additional $140 million equity investment. The focus of this collaboration is to advance the development of cutting-edge treatments for critical medical conditions in[…]

NKARTA: Recent IP and Promising Results in a Clinical Trial with CD19 CAR- Modified Natural Killer Cells

Posted on by

SOPHIA ANTIPOLIS, France – August 03, 2023 │ Today, immunotherapy is essential in cancer treatment. This field is therefore in full expansion and a lot of innovative therapies are emerging. In 2017, the FDA approval of two CAR-T cells therapies (KYMRIAH™ from Novartis and YESCARTA™ from Kite Pharma, a Gilead company) has enable the development[…]